Trial Profile
A Phase II, Multi-centre Study Investigating the Safety and Efficacy of Ofatumumab and Bendamustine Combination in Patients With Untreated or Relapsed Chronic Lymphocytic Leukaemia (CLL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 04 May 2016 Status changed from active, no longer recruiting to completed.
- 02 Aug 2013 Planned end date changed from 1 May 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 02 May 2013 Topline results were reported in a Genmab media release.